Evidence map›Paper›PMID 30276272›Full record

ReviewBrain circulation

Biomarkers for acute diagnosis and management of stroke in neurointensive care units.

Olena Y Glushakova, Alexander V Glushakov, Emmy R Miller, Alex B Valadka, Ronald L Hayes

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05300997 (Translational Immunodiagnostics in Suspected Stroke), which is not on this map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05300997 recruitingnot on this map

Translational Immunodiagnostics in Suspected Stroke (TrImS): A Two-centre, Pragmatic, Prospective, Observational Study

Typeobservational_patient_registrySponsorThe University of Hong KongRan2022 to 2027Enrolled650ConditionsAcute Ischemic Stroke, Haemorrhagic Stroke, Transient Ischemic Attacks, Cardioembolic StrokeArmsBiomarker blood draw and saliva collection
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Review
  10. Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study Conducted in the Emergency Department.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  11. Observational
  12. Article
  13. Review
  14. Clinical Markers and Diagnostics for Diagnosing Cerebral Infarction.CNS & neurological disorders drug targets · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Olena Y GlushakovaDepartment of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Alexander V GlushakovDepartment of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Emmy R MillerDepartment of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Alex B ValadkaDepartment of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Ronald L HayesBanyan Biomarkers, Inc., Alachua, Florida, USA.
Virginia Commonwealth University · USBanyan Biomarkers (United States) · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of current management of critically ill stroke patients depends on rapid assessment of the type of stroke, ischemic or hemorrhagic, and on a patient's general clinical status. Thrombolytic therapy with recombinant tissue plasminogen activator (r-tPA) is the only effective treatment for ischemic stroke approved by the Food and Drug Administration (FDA), whereas no treatment has been shown to be effective for hemorrhagic stroke. Furthermore, a narrow therapeutic window and fear of precipitating intracranial hemorrhage by administering r-tPA cause many clinicians to avoid using this treatment. Thus, rapid and objective assessments of stroke type at admission would increase the number of patients with ischemic stroke receiving r-tPA treatment and thereby, improve outcome for many additional stroke patients. Considerable literature suggests that brain-specific protein biomarkers of glial [i.e. S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP)] and neuronal cells [e.g., ubiquitin C-terminal hydrolase-L1 (UCH-L1), neuron-specific enolase (NSE), αII-spectrin breakdown products SBDP120, SBDP145, and SBDP150, myelin basic protein (MBP), neurofilament light chain (NF-L), tau protein, visinin-like protein-1 (VLP 1), NR2 peptide] injury that could be detected in the cerebrospinal fluid (CSF) and peripheral blood might provide valuable and timely diagnostic information for stroke necessary to make prompt management and decisions, especially when the time of stroke onset cannot be determined. This information could include injury severity, prognosis of short-term and long-term outcomes, and discrimination of ischemic or hemorrhagic stroke. This chapter reviews the current status of the development of biomarker-based diagnosis of stroke and its potential application to improve stroke care.

Indexed as

Biomarkerbloodcerebrospinal fluid (CSF)clinical trialintracerebral hemorrhage (ICH)ischemic strokeserumtransient ischemic attacks (TIAs)

Identifiers

PMID30276272
PMCPMC6126247
OpenAlexW2318875567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.